Literature DB >> 27565507

Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"?

Norah A Terrault1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27565507     DOI： 10.1007/s10620-016-4281-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

2.  Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.

Authors:  Hsin-Ming Wang; Chao-Hung Hung; Chuan-Mo Lee; Sheng-Nan Lu; Jing-Houng Wang; Yi-Hao Yen; Kwong-Ming Kee; Kuo-Chin Chang; Po-Lin Tseng; Tsung-Hui Hu; Chien-Hung Chen
Journal:  J Gastroenterol Hepatol       Date:  2016-07       Impact factor: 4.029

Review 3.  New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.

Authors:  David Durantel; Fabien Zoulim
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

4.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.

Authors:  Jörg Petersen; Renate Heyne; Stefan Mauss; Jörg Schlaak; Willibald Schiffelholz; Christoph Eisenbach; Heinz Hartmann; Manfred Wiese; Klaus Boeker; Hanns-Friedrich Loehr; Christine John; Maria Leuschner; Christian Trautwein; Gisela Felten; Andreas Trein; Wolfgang Krause; Susanne Ruppert; Tobias Warger; Dietrich Hueppe
Journal:  Dig Dis Sci       Date:  2015-11-14       Impact factor: 3.199

5.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Authors:  Patrick Marcellin; E Jenny Heathcote; Maria Buti; Ed Gane; Robert A de Man; Zahary Krastev; George Germanidis; Sam S Lee; Robert Flisiak; Kelly Kaita; Michael Manns; Iskren Kotzev; Konstantin Tchernev; Peter Buggisch; Frank Weilert; Oya Ovung Kurdas; Mitchell L Shiffman; Huy Trinh; Mary Kay Washington; Jeff Sorbel; Jane Anderson; Andrea Snow-Lampart; Elsa Mondou; Joe Quinn; Franck Rousseau
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

6.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

7.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

Authors:  Patrick Marcellin; Sang Hoon Ahn; Xiaoli Ma; Florin A Caruntu; Won Young Tak; Magdy Elkashab; Wan-Long Chuang; Seng-Gee Lim; Fehmi Tabak; Rajiv Mehta; Joerg Petersen; Graham R Foster; Lillian Lou; Eduardo B Martins; Phillip Dinh; Lanjia Lin; Amoreena Corsa; Prista Charuworn; G Mani Subramanian; Hans Reiser; Hendrick W Reesink; Scott Fung; Simone I Strasser; Huy Trinh; Maria Buti; Giovanni B Gaeta; Aric J Hui; George Papatheodoridis; Robert Flisiak; Henry L Y Chan
Journal:  Gastroenterology       Date:  2015-10-08       Impact factor: 22.682

8.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Authors:  Ching-Lung Lai; Daniel Shouval; Anna S Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard Colonno; Lori Fernandes
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

9.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.

Authors:  Patrick Marcellin; Fabien Zoulim; Christophe Hézode; Xavier Causse; Bruno Roche; Régine Truchi; Arnaud Pauwels; Denis Ouzan; Jérôme Dumortier; Georges-Philippe Pageaux; Marc Bourlière; Ghassan Riachi; Jean-Pierre Zarski; Jean-François Cadranel; Valérie Tilliet; Christiane Stern; Pascal Pétour; Olivier Libert; Silla M Consoli; Dominique Larrey
Journal:  Dig Dis Sci       Date:  2016-01-28       Impact factor: 3.199
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.